19 Student Name: Miao Wang Net ID: mxw142330 Case Study 1 Biopure Case Questions: 1. Hemopure: a. Identify relevant market segments and speculate whether the product is valuable to each segment at the suggested prices ($600-$800) As the case said the Biopure in human market‚ sometime the Hemopure could be $600-$800 per unit‚ which is very higher price than the Oxyglobin. This high price product which relevant market segments should be taken this price level ‚ following the attach Exhibit 5 excel
Free Blood Red blood cell Blood transfusion
Marketing Management – Assignment No. 2 Topic – Product Pricing (Biopure Case) CASE ANALYSIS for Biopure with respect to Pricing of Oxyglobin Our group analyzed the case and concluded that price of oxyglobin should be determined on perceived value approach. We calculated perceived value from case data and arrived at a price of $181. We are planning to launch it at a price of $175 to Vet so that there is some customer incentive to purchase and at same time‚ there is minimum ‘money left
Premium Price Blood Pricing
Company Biopure Corporation (“Biopure”) was founded in 1984 with the primary goal of developing a human blood substitute‚ a product with the oxygen-carrying property of blood but without many of the limitations of donated blood. No blood substitute has received approval for any use anywhere in the world‚ but Biopure is one of three promising competitors in the field. After many years of research and development‚ Biopure just received FDA approval for the commercial launch of Oxyglobin‚ a veterinary
Premium Blood transfusion Blood
INTEROFFICE MEMORANDUM TO: CARL RAUSCH‚ CEO‚ BIOPURE FROM: XXXXXXXXXX‚ MARKETING ANALYST‚ BIOPURE SUBJECT: OXYGLOBIN LAUNCH DATE: 50 4/22/2010 This memorandum is to propose that Biopure prepare to launch Oxyglobin as quickly as possible. The product should be priced at approximately $150 per unit and be advertised and distributed to emergency care veterinarians for use in dogs. Significant efforts need to be made in trade publications to educate veterinarians in this
Premium Blood transfusion Blood Marketing
Brief Overview: Biopure has two new products namely Oxyglobin and Hemopure. Oxyglobin is a first of its kind‚ new blood substitute for the veterinary market and has passed all the tests and is ready for consumer use. Hemopure is another such blood substitute for the human market and it will take a minimum of two years to launch the product from now. There is a concern about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Whereas another point of view
Free Blood Blood transfusion
Biopure Corporation Case Study Richard Addington PHD Table of Contents 1. Executive Summary 2. Situation Analysis a. Human Blood Demand b. Human Blood Pricing c. RBC limitations 3. Internal Environment d. Strengths and weaknesses of Oxyglobin e. Strengths and weaknesses of Hemopure 4. External/Competitive Environment f. Baxter g. Northfield h. Biopure 5. Animal Blood Market 6. Marketing Plan i. Positioning j. Pricing
Premium Blood Blood transfusion
The key issue is to determine when Oxyglobin should be introduced to the market without jeopardizing Hemopure’s potential and how it should be marketed. In addressing the issue‚ the following were considered: a sensitivity analysis for potential consumption of different price series‚ associated revenues and costs‚ and gross profit from different distribution methods. It is recommended that Biopure: 1. Introduce Oxyglobin immediately at a price of $100 to veterinarians. 2. Have an
Premium Blood Blood transfusion Red blood cell
Decision Sheet – Biopure Corporation Marketing Objective – Whether to launch Oxyglobin now or delay it till the approval of Hemopure. If yes‚ then devise a marketing plan for Oxyglobin. Options – 1. Launch Oxyglobin in the market immediately. 2. Defer the launch of Oxyglobin now till Hemopure release. Recommendation – Biopure Corporation should immediately launch Oxyglobin priced at $200. Rationale – Applying SWOT Analysis to the situation: Strengths 1. FDA approval has already come
Premium Blood Blood transfusion Marketing
Biopure’s two products‚ Hemopure for human use‚ and Oxyglobin for animal veterinary use‚ both represented a new blood substitute based treatment for managing patients’ oxygen requirements in a broad range of potential medical applications. The main issue that is plaguing Biopure is how the possible launch of Oxyglobin will affect the future launch and pricing strategies of Hemopure‚ which could provide a larger return for their investment. Biopure’s strength lies in their ability to market its
Premium Blood Marketing Blood transfusion
Biopure Corporation Written Case Study I. Current Situation Audit A. Issue Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market. There is a perceived risk by Ted Jacobs‚ the VP of Human Clinical Trials
Free Blood Blood transfusion